Presymptomatic Detection and Monitoring of Alzheimer’s Disease Using a Multi‐Disease Diagnostic Platform Employing Autoantibodies as Blood‐based Biomarkers
Cassandra DeMarshall, Jeffrey Viviano, Mert Sahin, Robert Nagele, the Parkinson’s Study Group (PSG), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) · 2025
Read Presymptomatic Detection and Monitoring of Alzheimer’s Disease Using a Multi‐Disease Diagnostic Platform Employing Autoantibodies as Blood‐based Biomarkers by Cassandra DeMarshall, Jeffrey Viviano, Mert Sahin, Robert Nagele, the Parkinson’s Study Group (PSG), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716950.txt.
Description
Cassandra DeMarshall and colleagues test a blood panel for early Alzheimer's detection, in work from 2025. Brain changes for this disease can start a decade before clear symptoms appear. Early proof would let care and trial entry start while damage is still limited.
A custom panel of self antibody markers in blood forms the test base. Past work split early stage patients from matched controls with high accuracy scores. The same markers flagged healthy people who later slipped to impairment or full disease. Current work checks the test build with strict lab validation steps for repeat use. The authors frame the blood test as cheap, non invasive screening for wide use.
Catalog record
| CREATOR | Cassandra DeMarshall, Jeffrey Viviano, Mert Sahin, Robert Nagele, the Parkinson’s Study Group (PSG), and the Alzheimer’s Disease Neuroimaging Initiative (ADNI) |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |